Seattle Genetics, Inc. and Millennium: The Takeda Oncology Company to Collaborate with Ventana Medical Systems, Inc. on Companion Diagnostic for ADCETRIS™ in CD30-Positive Malignancies

BOTHELL, Wash.& CAMBRIDGE, Mass. & TUCSON, Ariz.--(BUSINESS WIRE)--Seattle Genetics, Inc. (Nasdaq:SGEN) and Millennium: The Takeda Oncology Company, a wholly owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502), today announced that they have formed a collaboration with Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group. Under the collaboration agreement, Ventana will seek to develop, manufacture and commercialize a molecular companion diagnostic test with the goal of identifying patients who might respond to treatment with ADCETRIS based on CD30 expression levels in their tissue specimens. As part of the ongoing clinical development of ADCETRIS, Millennium and Seattle Genetics are planning two phase III studies that will use the companion diagnostic, one in CD30-positive cutaneous T-cell lymphoma (CTCL) and the other in CD30-positive mature T-cell lymphomas (MTCL).